This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tam, V. H.
Right arrow Articles by Lewis, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tam, V. H.
Right arrow Articles by Lewis, R. E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2005, p. 3624-3630, Vol. 49, No. 9
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.9.3624-3630.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa

Vincent H. Tam,1* Amy N. Schilling,1 Giao Vo,1 Samer Kabbara,1 Andrea L. Kwa,2 Nathan P. Wiederhold,1,{dagger} and Russell E. Lewis1

University of Houston College of Pharmacy, Houston, Texas,1 Department of Pharmacy, Singapore General Hospital, Singapore2

Received 30 March 2005/ Returned for modification 25 May 2005/ Accepted 25 June 2005

Despite limited data, polymyxin B (PB) is increasingly used clinically as the last therapeutic option for multidrug-resistant (MDR) gram-negative bacterial infections. We examined the in vitro pharmacodynamics of PB against four strains of Pseudomonas aeruginosa. Clonal relatedness of the strains was assessed by random amplification of polymorphic DNA. Time-kill studies over 24 h were performed with approximately 105 and 107 CFU/ml of bacteria, using PB at 0, 0.25, 0.5, 1, 2, 4, 8, and 16x MIC. Dose fractionation studies were performed using an in vitro hollow-fiber infection model (HFIM) against a wild-type and a MDR strain. Approximately 105 CFU/ml of bacteria were exposed to placebo and three regimens (every 8 h [q8h], q12h, and q24h) simulating the steady-state unbound PB pharmacokinetics resulting from a daily dose of 2.5 mg/kg of body weight and 20 mg/kg (8 times the clinical dose). Samples were obtained over 4 days to quantify PB concentrations, total bacterial population, and subpopulation with reduced PB susceptibility (>3x MIC). The bactericidal activity of PB was concentration dependent, but killing was significantly reduced with a high inoculum. In HFIM studies, a significant reduction in bacterial load was seen at 4 h in all active regimens, but selective amplification of the resistant subpopulation(s) was apparent at 24 h with the clinical dose (both strains). Regrowth was eventually observed in all dosing regimens with the MDR strain, but its occurrence was prevented in the wild-type strain by using 8 times the clinical dose (regardless of dosing intervals). Our results suggested that the bactericidal activity of PB was concentration dependent and appeared to be related to the ratio of the area under the concentration-time curve to the MIC.

* Corresponding author. Mailing address: University of Houston College of Pharmacy, 1441 Moursund Street, Houston, TX 77030. Phone: (713) 795-8316. Fax: (713) 795-8383. E-mail: vtam{at}uh.edu.

{dagger} Present address: University of Texas Health Science Center at San Antonio, San Antonio, Tex.

Antimicrobial Agents and Chemotherapy, September 2005, p. 3624-3630, Vol. 49, No. 9
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.9.3624-3630.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Tam, V. H., Hou, J., Kwa, A. L., Prince, R. A. (2009). Comment on: Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. J Antimicrob Chemother 63: 627-628 [Full Text]  
  • Cao, G., Ali, F. E. A., Chiu, F., Zavascki, A. P., Nation, R. L., Li, J. (2008). Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. J Antimicrob Chemother 62: 1009-1014 [Abstract] [Full Text]  
  • Pastewski, A. A, Caruso, P., Parris, A. R, Dizon, R., Kopec, R., Sharma, S., Mayer, S., Ghitan, M., Chapnick, E. K (2008). Parenteral Polymyxin B Use in Patients with Multidrug-Resistant Gram-Negative Bacteremia and Urinary Tract Infections: A Retrospective Case Series. The Annals of Pharmacotherapy 42: 1177-1187 [Abstract] [Full Text]  
  • Landman, D., Georgescu, C., Martin, D. A., Quale, J. (2008). Polymyxins Revisited. Clin. Microbiol. Rev. 21: 449-465 [Abstract] [Full Text]  
  • Khalil, H., Chen, T., Riffon, R., Wang, R., Wang, Z. (2008). Synergy between Polyethylenimine and Different Families of Antibiotics against a Resistant Clinical Isolate of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52: 1635-1641 [Abstract] [Full Text]  
  • Bergen, P. J., Li, J., Nation, R. L., Turnidge, J. D., Coulthard, K., Milne, R. W. (2008). Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother 61: 636-642 [Abstract] [Full Text]  
  • Zavascki, A. P., Goldani, L. Z., Li, J., Nation, R. L. (2007). Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 60: 1206-1215 [Abstract] [Full Text]  
  • Tam, V. H., Schilling, A. N., Poole, K., Nikolaou, M. (2007). Mathematical modelling response of Pseudomonas aeruginosa to meropenem. J Antimicrob Chemother 60: 1302-1309 [Abstract] [Full Text]  
  • Scheetz, M. H., Qi, C., Warren, J. R., Postelnick, M. J., Zembower, T., Obias, A., Noskin, G. A. (2007). In Vitro Activities of Various Antimicrobials Alone and in Combination with Tigecycline against Carbapenem-Intermediate or -Resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51: 1621-1626 [Abstract] [Full Text]  
  • Falagas, M. E., Kasiakou, S. K., Tsiodras, S., Michalopoulos, A. (2006). The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.. Clin Med Res 4: 138-146 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»